Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics as Medicines: An Emerging New Paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 209-219
Closed Access | Times Cited: 296

Showing 26-50 of 296 citing articles:

CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 1, pp. 55-67
Closed Access | Times Cited: 16
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Altered network hub connectivity after acute LSD administration
Felix Müller, Patrick C. Dolder, André Schmidt, et al.
NeuroImage Clinical (2018) Vol. 18, pp. 694-701
Open Access | Times Cited: 160
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Albert Garcia‐Romeu, William A. Richards
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 291-316
Closed Access | Times Cited: 153
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Peter S. Hendricks
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 331-342
Closed Access | Times Cited: 145
Psychedelic Drugs in Biomedicine
Evan J. Kyzar, Charles D. Nichols, Raul R. Gainetdinov, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 11, pp. 992-1005
Closed Access | Times Cited: 137
Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents
Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 7, pp. 3261-3270
Open Access | Times Cited: 136
Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
Lukasz Smigielski, Michael Kometer, Milan Scheidegger, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 135
Mushroom-Derived Indole Alkaloids
Joshua A. Homer, Jonathan Sperry
Journal of Natural Products (2017) Vol. 80, Iss. 7, pp. 2178-2187
Closed Access | Times Cited: 134
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Lindsay P. Cameron, Charlie J. Benson, Lee E. Dunlap, et al.
ACS Chemical Neuroscience (2018) Vol. 9, Iss. 7, pp. 1582-1590
Open Access | Times Cited: 133
Psilocybin: from ancient magic to modern medicine
David E. Nichols
The Journal of Antibiotics (2020) Vol. 73, Iss. 10, pp. 679-686
Closed Access | Times Cited: 115
Ethics and ego dissolution: the case of psilocybin
William Smith, Dominic A. Sisti
Journal of Medical Ethics (2020) Vol. 47, Iss. 12, pp. 807-814
Open Access | Times Cited: 102
Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials
Ana Sofia Vargas, Ângelo Luís, Mário Barroso, et al.
Biomedicines (2020) Vol. 8, Iss. 9, pp. 331-331
Open Access | Times Cited: 99
The History of Psychedelics in Psychiatry
David E. Nichols, Hannes Walter
Pharmacopsychiatry (2020) Vol. 54, Iss. 04, pp. 151-166
Open Access | Times Cited: 95
Chronic pain and psychedelics: a review and proposed mechanism of action
Joel Castellanos, C. Leonard Woolley, Kelly Bruno, et al.
Regional Anesthesia & Pain Medicine (2020) Vol. 45, Iss. 7, pp. 486-494
Closed Access | Times Cited: 89
Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth
Calvin Ly, Alexandra C. Greb, Maxemiliano V. Vargas, et al.
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 452-460
Open Access | Times Cited: 86
Psychedelic Microdosing: Prevalence and Subjective Effects
Lindsay P. Cameron, Angela Nazarian, David E. Olson
Journal of Psychoactive Drugs (2020) Vol. 52, Iss. 2, pp. 113-122
Open Access | Times Cited: 82
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 65
Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice
Yuria Celidwen, Nicole Redvers, Cicilia Githaiga, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100410-100410
Open Access | Times Cited: 62
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Bruno Roméo, Marianne Hermand, Amélie Petillion, et al.
Journal of Psychiatric Research (2021) Vol. 137, pp. 273-282
Open Access | Times Cited: 59
Psychedelics as Tools for Belief Transmission. Set, Setting, Suggestibility, and Persuasion in the Ritual Use of Hallucinogens
David Dupuis
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 58
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
Grant C. Glatfelter, Eline Pottie, John S. Partilla, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 11, pp. 1181-1196
Open Access | Times Cited: 55
Psychedelics and Neural Plasticity: Therapeutic Implications
Steven F. Grieco, Eero Ċastrén, Gitte M. Knudsen, et al.
Journal of Neuroscience (2022) Vol. 42, Iss. 45, pp. 8439-8449
Open Access | Times Cited: 44
Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
Peter Oehen, Peter Gasser
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 41
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
Johannes T. Reckweg, C. J. Van Leeuwen, Cécile Henquet, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 35

Scroll to top